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Summary. Statistical methodology plays a crucial role in drug regulation. Decisions by the
US Food and Drug Administration or European Medicines Agency are typically made based
on multiple primary studies testing the same medical product, where the two-trials rule is the
standard requirement, despite shortcomings. A new approach is proposed for this task based
on the harmonic mean of the squared study-specific test statistics. Appropriate scaling ensures
that, for any number of independent studies, the null distribution is a χ2-distribution with 1
degree of freedom. This gives rise to a new method for combining one-sided p-values and
calculating confidence intervals for the overall treatment effect. Further properties are discussed
and a comparison with the two-trials rule is made, as well as with alternative research synthesis
methods.An attractive feature of the new approach is that a claim of success requires each study
to be convincing on its own to a certain degree depending on the overall level of significance
and the number of studies. The new approach is motivated by and applied to data from five
clinical trials investigating the effect of carvedilol for the treatment of patients with moderate to
severe heart failure.
Keywords: Combining p-values; Drug regulation; Evidence synthesis; Two-trials rule; Type I
error
1. Introduction
Research synthesis has been characterized as the process of combining the results of multiple
primary studies aimed at testing the same conceptual hypothesis. Meta-analysis is the preferred
technique of quantitative research synthesis, as it provides overall effect estimates with confi-
dence intervals and p-values through pooling of study results and allows for the incorporation
of heterogeneity between studies. However, meta-analysis can be criticized as a too weak tech-
nique if the goal is to substantiate an original claim through one or more additional independent
studies. Specifically, a significant overall effect estimate may occur even if some of the individual
studies have not been convincing on their own, perhaps even with effect estimates in the wrong
direction. This may be acceptable if the unconvincing studies have been small, but seems less
tolerable if each study was well powered and well conducted.
For example, consider the results from five clinical trials on the effect of carvedilol, a beta-
and alpha-blocker and an antioxidant drug for the treatment of patients with moderate to severe
heart failure, on mortality (see Fisher (1999a), Table 1). One-sided p-values (from log-rank tests)
and estimated hazard ratios HR are shown in Table 1, indicating a reduction in instantaneous
risk of death between 28% and 78% across the various studies.
A meta-analysis could be applied to the data that are shown in Table 1, but the drug regu-
Address for correspondence: Leonhard Held, Epidemiology, Biostatistics and Prevention Institute and Center
for Reproducible Science, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland.
E-mail: leonhard.held@uzh.ch
698 L. Held
Table 1. Results from five clinical trials on the
effect of carvedilol for the treatment of patients
with moderate to severe heart failure†
Study p-value HR log(HR) SE
220 0.00025 0.27 −1:31 0.41
240 0.0245 0.22 −1:51 0.85
223 0.128 0.72 −0:33 0.29
221 0.1305 0.57 −0:56 0.51
239 0.2575 0.53 −0:63 1.02
†Shown are one-sided p-values, estimated hazard
ratios HR and the associated log-hazard-ratios
log(HR) with standard errors SE.
lation industry (including the US Food and Drug Administration) typically relies instead on
the ‘two-trials rule’ (Senn, 2007; Kay, 2015), which is also known as the ‘two-pivotal-study
paradigm’ (Hlavin et al., 2016), for approval. This simple decision rule requires ‘at least two ad-
equate and well-controlled studies, each convincing on its own, to establish effectiveness’ (Food
and Drug Administration (1998), page 3). This is usually achieved by independently replicating
the result of a first study in a second study, both significant at one-sided level α=0:025. How-
ever, in modern drug development often more than two trials are conducted and it is unclear
how to extend the two-trials rule to this setting. Requiring at least two out of n > 2 studies
to be significant is too lax a criterion if the results from the non-significant studies are not
taken into account at all. However, requiring all n studies to be significant is too stringent.
This problem applies to the carvedilol example, where two trials are significant at the 2.5%
level (one just with p = 0:0245) but where it is unclear whether the remaining three studies
(with p-values 0.128, 0.1305 and 0.2575) can be considered as sufficiently ‘convincing on its
own’.
This has led statistical researchers to discuss the possibility of pooling the results from the
various studies into one p-value (Fisher, 1999b; Darken and Ho, 2004; Shun et al., 2005). Fisher’s
method to combine p-values (Fisher, 1958) is often used for this task, e.g. in Fisher (1999a) for
the carvedilol example. However, Fisher’s method shares the problems of a meta-analysis as it
can produce a significant overall result even if one of the trials was negative. For example, one
completely unconvincing trial with (one-sided) p=0:5 combined with a convincing second trial
with p= 0:0001 would give Fisher’s p= 0:0005 < 0:000625 = 0:0252, and so a claim of success
with respect to the type I error rate of the two-trials rule. In contrast, two trials both with p=0:01
would give Fisher’s p=0:001 and so would not be considered as successful. Both decisions seem
undesirable from a regulator’s perspective.
The two-trials rule therefore remains the standard in drug regulation, but has additional
deficiencies even for n=2 studies, where independent p-value thresholding at 0:025 may lead to
decisions that are the opposite to what the evidence warrants. For example, two trials both with
p=0:024 will lead to drug approval but carry less evidence for a treatment effect than one trial
with p=0:026 and the other trial with p=0:001, which would, however, not pass the two-trials
rule. Rosenkrantz (2002) has therefore proposed a method to claim efficacy if one of two trials
is significant whereas the other just shows a trend. He combined the two-trials rule with Fisher’s
method and a relaxed criterion for significance of the two individual trials, say 2α. A similar
approach has been proposed by Maca et al. (2002) using meta-analytic pooling rather than
Fisher’s combined method. The arbitrariness in the choice of the relaxed significance criterion
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is less attractive, though, and it is not obvious how to extend the methods to results from more
than two studies.
In this paper I develop a new method that addresses these issues and leads to more appro-
priate inferences: the harmonic mean χ2-test described in Section 2. At the type I error rate
0:0252 of the two-trials rule, the test proposed comes to opposite conclusions for the exam-
ples that were mentioned above: contrary to Fisher’s method, it leads to approval of two trials
both with p= 0:01, but not to approval if one has p= 0:0001 and the other has p= 0:5. Con-
trary to the two-trials rule, it leads to approval of one trial with p = 0:026 and the other with
p = 0:001, but not to approval if both trials have p = 0:024. The work is motivated from a re-
cent proposal how to evaluate the success of replication studies (Held, 2020) and is based on
the harmonic mean of the squared Z-scores. It can include weights for the individual studies
and can be calibrated to ensure exact type I error control and to compute an overall p-value;
see Section 2.1. Furthermore, the new approach implies useful bounds on the study-specific
p-values, thus formalizing the meaning of ‘at least two adequate and well-controlled studies,
each convincing on its own’. It can also be used to calculate a confidence interval for the over-
all treatment effect; see Section 2.2. The approach will be compared with the two-trials rule
in Section 3 and applied to the carvedilol data in Section 4. I close with some discussion in
Section 5.
2. The harmonic mean χ2-test
Suppose that one-sided p-values p1, : : : , pn are available from n independent studies. How can
we combine the p-values into one p-value? Cousins (2008) compared some of the more promi-
nent references on this topic. Among them is Stouffer’s method, which is based on the Z-scores
Zi =Φ−1.1−pi/; here Φ−1.·/ denotes the quantile function of the standard normal distribution.
Under the assumption of no effect, the test statistic Z =Σni=1Zi=
√
n is standard normally dis-
tributed. The corresponding p-value forms the basis of the ‘pooled trials rule’ and is equivalent
to investigating significance of the overall effect estimate from a fixed effects meta-analysis (Senn
(2007), section 12.2.8). Fisher’s method is also commonly used and compares −2Σni=1 log.pi/
with a χ2-distribution with 2n degrees of freedom to compute a combined p-value. Both Stouf-
fer’s and Fisher’s method can be extended to incorporate weights, where the null distribution
of Fisher’s method no longer has a convenient form (Good, 1955). There is a large literature on
the comparison of these and other methods for the combination of p-values, such as Littell and
Folks (1973), Berk and Cohen (1979), Westberg (1985) and Heard and Rubin-Delanchy (2018).
Here I propose a new approach to assess the overall evidence for a treatment effect based on












This form is motivated from the special case of n = 2 successive studies, one original and one
replication, where a reverse Bayes approach for the assessment of replication success has re-
cently been described (Held, 2020). If the two studies have equal precision (i.e. sample size),
the assessment of replication success does not depend on the order of the two studies and is
based on the test statistic 1=.1=Z21 + 1=Z
2
2/; compare Held (2020), equation (9). Equation (1)
extends this to n studies with an additional multiplicative factor n2, which ensures that the null
distribution of equation (1) does not depend on n. Weights w1, : : : , wn can also be introduced in













should be used. The factor w2 ensures that the null distribution of equation (2) does not depend
on the weights w1, : : : , wn; nor on n.
The specific form of equation (2) deserves some additional comments. In practice we often
have Zi = θ̂i=σi where σi =κ=
√
mi is the standard error of the effect estimate θ̂i, κ
2 is the one-unit
variance and mi the sample size of study i. If we use weights wi = 1=σ2i equal to the precision
of the effect estimates, equation (2) can be written as the unweighted harmonic mean θ̂
2
H of the
squared effect estimates θ̂
2










In the special case of equal sample sizes m1 =: : :=mn =m, the scaling factor reduces to nm.
There is a subtle difference between the two formulations (1) and (3). The unweighted test
statistic (1) is based on the harmonic mean of the squared study-specific test statistics Z2i ,
i = 1, : : : , n. If we increase the sample size of the different studies, statistics (1) will therefore
also tend to increase if there is a true non-zero effect. However, test statistic (3) is based on the
harmonic mean θ̂
2
H of the squared study-specific effect estimates θ̂
2
i , which should not be much
affected by any increase of study-specific sample sizes because the study-specific estimates θ̂i
should then stabilize around their true values. It is the scaling factor w2=n that will react to
an increase in study-specific sample sizes. The test statistic (3) can thus be factorized into a
component depending on sample sizes and a component depending on effect sizes.
2.1. p-values
Using properties of Lévy distributions it can be shown that, under the null hypothesis of no
effect, the distribution of both statistic (1) and statistic (2) is χ2 with 1 degree of freedom; see
Appendix A for details. We can thus compute an overall p-value pH from equation (1) or (2)
based on the χ2.1/ distribution function. However, we must be careful since equation (1) does
not take the direction of the effects into account. Usually we are interested in a predefined
direction of the underlying effect, say H1 :θ > 0 against H0 :θ=0, and we will have to adjust for
the fact that statistics (1) and (2) can be large for any of the 2n possible combinations of the
signs of Z1, : : : , Zn, with all these combinations being equally likely under the null hypothesis.
Since we are interested only in the case where all signs are positive, we must adjust the p-value
accordingly.
To be specific, suppose that all studies have a positive effect and the observed test statistic (1)
or (2) is respectively X2 =x2 or X2w =x
2 and let x=
√
x2. The overall p-value from the significance








Likewise we can obtain the critical value
cH ={Φ−1.1−2n−1αH/}2 .5/
for the test statistic (1) or (2) to control the type I error rate at some overall level of significance
αH. Note that the overall p-value (4) cannot be larger than 1=2
n as it should, since under the
null hypothesis the probability of obtaining n positive results is 1=2n. We are interested only in
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this case, so if at least one of the studies has a negative effect I suggest reporting the inequality
pH > 1=2
n, e.g. pH > 0:25 for n=2 studies.
In what follows I restrict attention to the unweighted test statistic X2 given in equation
(1). Let Zi = zi denote the observed test statistic in the ith study. I assume that zi > 0 for all
i = 1, : : : , n, i.e. all effects go in the right direction. First note that the smallest squared test
statistic z2min =min{z
2
1, : : : , z
2
n} multiplied by the number of studies n is an upper bound on the










where the second inequality holds for all i=1, : : : , n. This implies that x2 n2z2i for the observed




If pH αH is required for a claim of success at level αH, then obviously Pr{χ
2.1/n2z2i }=2
n αH
must hold, which can be rewritten as zi 
√
cH=n with cH given in equation (5). The restriction




The right-hand side of inequality (6) is thus a necessary but not sufficient bound on the study-
specific p-values for a claim of success.
It is also possible to derive the corresponding sufficient bound. Assume that all p-values are
equal (i.e. z21 =: : := z
2
n); then the condition X





the sufficient bound on zi differs from the necessary bound by a factor of
√
n. The restriction






For n= 1 the necessary and sufficient bounds in inequalities (6) and (7) both reduce to αH, as
they should.
The two-trials rule for drug approval is usually implemented by requiring that each study is
significant at the one-sided level α=1=40=0:025, so the probability of n=2 significant positive
trials when there is no treatment effect is α2 =1=1600=0:000625. The necessary and sufficient
bounds in inequalities (6) and (7) respectively are shown in Table 2 for αH = 1=1600 (the two-
trials rule), 1/31574 (the 4σ-rule) and 1/3488556 (the 5σ-rule). The level of significance of the
kσ-rule is based on a normally distributed test statistic T ∼N.0, σ2/ with zero mean and defined
as Pr.T > kσ/ = 1 − Φ.k/. The 5σ-rule (k = 5) was used to declare the discovery of the Higgs
boson (Johnson (2013), section 3.2.1). The two-trials rule corresponds to k = 3:23, so the level
of significance of the 4σ-rule is between the two-trials rule and the 5σ-rule.
The first row of Table 2 reveals that, for level 1/1600, the requirement pi  0:065, i= 1, 2, is
necessary for claiming success based on n = 2 studies. If one of the two studies has a p-value
that is larger than 0.065, a claim of success at level αH = 1=1600 is thus impossible, no matter
how small the other p-value is. Both p-values being smaller than 0.016 is sufficient for a claim of
success at that level. With increasing n both bounds increase; for example for n=6 studies it is
necessary that each p-value is smaller than 0.37 whereas it is sufficient that each p-value is smaller
than 0.20. Decreasing the level of significance from 1/1600 to 1/31574 gives similar bounds for
n+ 1 rather than n studies, and likewise for another decrease from 1/31574 to 1/3488556. For
example, the necessary bound is 0.17 for αH = 1=1600 and n = 3, 0.19 for αH = 1=31574 and
n=4, and again 0.19 for αH =1=3488556 and n=5.
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Table 2. Necessary and sufficient bounds on the one-sided study-specific
p-values for overall significance level αH and various numbers of studies n
αH Bound Results for the following values of n:
n=2 n=3 n=4 n=5 n=6
1/1600 Necessary 0.065 0.17 0.26 0.32 0.37
Sufficient 0.016 0.053 0.099 0.15 0.20
1/31574 Necessary 0.028 0.11 0.19 0.26 0.30
Sufficient 0.0034 0.017 0.041 0.071 0.10
1/3488556 Necessary 0.0075 0.058 0.13 0.19 0.24
Sufficient 0.00029 0.0032 0.011 0.024 0.04
2.2. Confidence intervals
The harmonic mean χ2-test is not directly linked to an overall effect estimate and a confidence
interval. However, the test can be inverted to obtain a confidence interval. Two extensions of
the method are required to do so. First, we need to consider test statistics Zi = .θ̂i −µ/=σi for
the more general point null hypothesis H0 : θ =µ. Second, to compute a two-sided confidence
interval we need to calculate a two-sided rather than one-sided p-value. A two-sided p-value
defined as twice the one-sided p-value (4) represents the common scenario that an initial study
is two sided and all following studies aim to substantiate the effect of the first study including
its direction and so are one sided. The two-sided p-value 2pH can hence be evaluated not only if
all effect estimates are positive, but also if all effect estimates are negative. If the effect estimates
are not all in the same direction I now suggest reporting 2pH > 1=2
n−1.
We can now calculate a p-value function (see Infanger and Schmidt-Trucksäss (2019) for a
recent review), displaying the two-sided harmonic mean p-value as a function of µ. A two-sided
confidence interval at any level γ > 1−1=2n−1 can then be defined as the set of µ-values where
the two-sided p-value is larger than 1−γ. An example is given in Section 4.
3. Comparison with the two-trials rule
Suppose that both studies have a positive effect in the right direction and the observed test
statistic (1) is X2 = x2. The harmonic mean χ2 p-value (4) now reduces to pH = {1 −Φ.x/}=2.
A critical value for the test statistic (1) can also be calculated by using inequality (5). For
αH =0:0252 and n=2 we obtain the critical value cH =9:14.
Fig. 1 compares the region for drug approval based on the two-trials rule with the proposed
harmonic mean χ2-test. Shown are two versions of the latter, the ‘controlled’ version based
on αH =0:0252, i.e. critical value cH =9:14, and a ‘liberal’ version with critical value 7.68. The
liberal version has been computed by equating the right-hand side of inequality (7) with 0.025
and solving for cH. The liberal version thus ensures that approval by the two-trials rule always
leads to approval by the harmonic mean χ2-test. The type I error rate of the liberal version is
0.00139, inflated by a factor of 2.23 compared with the α2 =0:0252-level.
Also shown in Fig. 1 is the corresponding region for drug approval of the pooled and combined
method, both controlled at type I error 0:0252. Both methods compensate smaller intersections
with the two-trials rejection region with additional regions of rejection where one of the trials
shows only weak or even no evidence for an effect. It is interesting to see that the harmonic mean
χ2-test is closer to the two-trials rule than Stouffer’s pooled or Fisher’s combined method, which

































Fig. 1. Comparison of various approaches for drug approval depending on (a) the p-values p1 and p2 and
(b) the Z-values Z1 and Z2 ( , rejection region of the two-trials rule; , harmonic (liberal); ,
harmonic (controlled); , pooled; , combined): the rejection region of the other methods is (a)
below or (b) above the corresponding curves; all methods control the type I error rate at 0:000625 except
for the liberal version of the harmonic mean χ2-test, which has type I error rate 0:00139; the contour lines
in (b) represent the distribution of Z1 and Z2 under the alternative if the two studies have 80% power at the
one-sided 2.5% level of significance
is particularly good to see in the z-scale shown in Fig. 1(b). Stouffer’s and Fisher’s methods suffer
from the possibility of approval if one of the p-values is very small whereas the other is far from
traditional significance. A highly significant p-value may actually guarantee approval through
Fisher’s method, no matter how large the p-value from the other study is. This is not possible
for Stouffer’s method, but it may still happen that the effects from the two studies go in different
directions with the combined effect being significant. As a consequence, the sufficient p-value
bound, which is shown in Fig. 1(a), is considerably smaller for the pooled (0.011) and combined
(0.008) method than for the harmonic mean χ2-test (0.016) with the same type I error rate.
These features make both the pooled and the combined method less suitable for drug approval.
The harmonic mean χ2-test can be significant only if both p-values are small (less than
0.065). This has been discussed in Section 2 and can also be seen from Fig. 2, which shows
the conditional power for drug approval given the p-value p1 from the first study. The values
represent the power to detect the observed effect from the first study with a second study of equal
design and sample size. The two-trials rule has conditional power as described by Goodman
(1992), but with a discontinuity at 0.025. The power curves of the two harmonic mean χ2-tests
(calculated with the results given in Held (2020), section 4) are smooth, quickly approaching
zero at p1 =0:065 and p1 =0:083. Both the combined and the pooled method have longer tails
with non-zero conditional power even for a larger p-value of the first study. Here the conditional
power of the combined method can be derived as 1−Φ[Φ−1.p1/−Φ−1{min.1, c=p1/}] where c=
Pr{χ2.4/αH}. The conditional power of the pooled method turns out to be 1−Φ{2Φ−1.p1/−√
2Φ−1.αH/}.
Of central interest in drug development is often the ‘project power’ for a claim of success
before the two trials are conducted (Maca et al., 2002). It is well known (Matthews, 2006) that,
under the alternative that was used to power the two trials, the distribution of Z1 and Z2 is
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Fig. 2. Power for drug approval conditional on the one-sided p-value of the first study (power values of
exactly 0 have been omitted: , two-trials rule; , pooled; , combined; , harmonic
(controlled); , harmonic (liberal))
Table 3. Individual trial power and project power of the various
methods for drug approval
Trial Project power (%)
power (%)
Two-trials Harmonic Combined Pooled
rule
70 49 56 58 61
80 64 71 74 77
90 81 87 90 91
95 90 94 96 97
N.µ, 1/ where µ=Φ−1.1−α/+Φ−1.1−β/, where 1−β is the power of each trial. We can thus
simulate independent Z1 and Z2 for α=0:025 and different values of the individual trial power
1 −β and compute the proportion of results with drug approval at level α2. This is shown in
Table 3 for the various methods.
As expected, the two-trials rule gives project power equal to .1−β/2, since the two trials are
assumed to be independent, each significant with probability 1 −β. The project power of the
type I error controlled harmonic mean χ2-test is 4–7 percentage points larger, depending on the
power of the two trials. The project power of the combined and pooled methods are even larger
but this comes at the price that approval may be granted even if one of the two trials was not
sufficiently convincing on its own.
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4. Application
Two advantages of the method proposed are that it allows for weighting and is readily applicable
to the case where results from more than two studies are available. Consider again the data shown
in Table 1 on the effect of carvedilol on mortality. Note that all p-values are below the necessary
success bound 0.32 at the level of the two-trials rule; compare with Table 2. Only the p-value of
study 239 is above the sufficient bound 0.15; otherwise we could already claim success with the
unweighted harmonic mean χ2-test.
Fisher (1999a) reported Fisher’s combined p-value, which is 0.00013. Stouffer’s unweighted
pooled test gives the p-value 0.00009; the weighted version gives p = 0:00018. For the latter
the weights have been chosen inversely proportional to the squared standard errors of the
associated log-hazard-ratios that are also shown in Table 1; see Appendix B for further details.
The harmonic mean χ2-test gives 0.00048 (unweighted) and 0.00034 (weighted); so slightly larger
values. Note that all these p-values are smaller than the threshold 0.000625 of the two-trials
rule.
I have also calculated two confidence intervals based on the inversion of the weighted har-
monic mean χ2-test as described in Section 2.2. The 99.875% confidence interval for the hazard
ratio θ goes from 0.17 to 0.97. The confidence level is selected to be compatible with the one-sided
type I error rate αH =0:000625 of the two-trials rule, as 1−2 ×0:000625=0:99875. The more
standard 95% confidence interval for the hazard ratio goes from 0.21 to 0.74. For comparison, a
random-effects meta-analysis gives the 95% confidence interval 0.25–0.77 (two-sided p=0:004).
A fixed effects meta-analysis gives the 95% confidence interval 0.32–0.72. The corresponding
two-sided p-value is 0.00035.
Suppose now that the p-value in study 223 (the largest study with the smallest standard error)
is twice as large, i.e. 0.256 rather than 0.128. This would be considered as unimportant by
many scientists, as both p-values are non-significant anyway and far from the standard 0.025
significance threshold. Keeping the standard error of the log-relative-risk fixed, the estimated
hazard ratio in this study is now 0.83 rather than 0.72.
This change has a noticeable effect on the method proposed: the unweighted and weighted
harmonic mean χ2-test p-values increase by a factor of 2.5 and 7.9 to 0.0012 and 0.0027 respec-
tively, so both would now fail the 0:0252 =0:000625-threshold for drug approval. The p-values
of the unweighted and weighted Stouffer’s test increase by only a factor of 2.3 and 3.5 to 0.00021
and 0.00061 respectively. Both p-values are still below the 0.000625-threshold, and this is also so
for Fisher’s combined p-value, which increases by a factor of 1.7 to 0.00022. This illustrates that
the harmonic mean χ2-test is more sensitive to studies with unconvincing results, i.e. relatively
small effect sizes with large p-values.
5. Discussion
There is considerable variation of clinical trial evidence for newly approved therapies (Downing
et al., 2014). New methods are required to provide better inferences for the assessment of piv-
otal trials supporting novel therapeutic approval. The harmonic mean χ2-test is an attractive
alternative to the two-trials rule as it has more power at the same type I error rate and avoids
the evidence paradoxes that may occur close to the 0.025-threshold. It provides a principled
extension to substantiate research findings from more than two trials, requesting each trial to be
convincing on its own, and allows for weights. It is worth noting that the method proposed is dif-
ferent from the harmonic mean p-value (Good, 1958; Wilson, 2019), where the null distribution
is more difficult to compute.
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The method implicitly assumes that each of the individual trials is well powered for realistic
treatment effects. The risk that the harmonic mean test fails increases substantially, if some
of the trials have low power. Implementation of this new method may therefore be seen as an
incentive to use sufficiently powered and properly conducted individual studies. Meta-analytic
techniques may be more suitable if some of the studies that are considered are underpowered
or if there is substantial heterogeneity between studies.
The two-trials rule is the standard for many indications, including many neurogenerative
and cardiovascular diseases. However, approval of treatments in areas of high medical need
may not follow the two-trials rule. An alternative approach is conditional approval based on
‘adaptive pathways’ (European Medicines Agency, 2016), where a temporary licence is granted
based on an initial positive trial. A second post-marketing clinical trial is then often required
to confirm or revoke the initial decision (Zhang et al., 2020). This setting has much in common
with replication studies that try to confirm original results in independent investigations (Held,
2020; Roes, 2020).
6. Availability of software
Software to perform the methodology that is described in this paper is available in the R pack-
age ReplicationSuccess which is available from R-Forge; use the R command install.
packages (‘‘ ReplicationSuccess ’’,repos=‘‘ http://R-Forge.R-project.
org ’’).
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Appendix A: The null distribution of the harmonic mean χ2-test statistic
Under the null hypothesis, Zi, i= 1, : : : , n, is standard normal distributed, so Z2i is χ
2 distributed with 1




/ distribution. The random variable Yi =1=Z2i is therefore inverse
gamma distributed, Yi ∼ IG. 12 ,
1
2
/, also known as the standard Lévy distribution: Yi ∼ Levy.0, 1/. More
generally, the Levy.0, c/ distribution corresponds to the IG. 1
2
, c/2) distribution and belongs to the class
of stable distributions (Uchaikin and Zolotarev (1999), section 2.3).
Now Z1, : : : , Zn are assumed to be independent, so Y1, : : : , Yn are also independent and we are interested
in the distribution of the sum Y =Y1 + : : :+Yn; compare with equation (1). The standard Lévy distribution
is stable, which means that the sum of independent standard Lévy random variables is again a Lévy random
variable: Y ∼Levy.0, n2/, which corresponds to an IG. 1
2
, n2=2/ distribution. Therefore 1=Y =1=Σni=11=Z
2
i
follows a G. 1
2




/ distribution, i.e. a χ2-
distribution with 1 degree of freedom.
The weighted version Y = w1Y1 + : : : + wnYn is also a Lévy random variable, Y ∼ Levy.0, w2/ where
w =Σni=1
√
wi; see Nolan (2018), proposition 1.17. Therefore X
2
w =w
2=Y in equation (2) also follows a χ2-
distribution with 1 degree of freedom. It is noteworthy that the χ2.1/ distribution of X2 and X2w holds even
under dependence of Z1, : : : , Zn, as described by Drton and Xiao (2016), conjecture 6.2, and proved by
Pillai and Meng (2016), theorem 2.2.
Appendix B: Further details on the carvedilol example
The data that were shown in Table 1 are taken from Fisher (1999a), Table 1, for the outcome mortality. The
discussion in Fisher (1999a), page 17, suggests that the p-values that are reported in Table 1 come from
Harmonic Mean χ2-test 707
a log-rank test. The relative risks that are reported in Table 1 appear to be ‘instantaneous relative risks’,
i.e. hazard ratios. I have calculated the standard error of the log-hazard-ratios from the limits of the 95%
confidence intervals that are also reported in Table 1. Note that there is an apparent discrepancy between
the p-value and the confidence interval reported for study 240, with the one-sided log-rank p-value being
just significant (p=0:0245) whereas the 95% confidence interval for the hazard ratio is from 0.04 to 1.14
and includes the reference value 1. Leaving rounding errors aside, the corresponding one-sided p-value
from a Wald-test is p=0:038. This does not much affect the harmonic mean χ2-test but the two-trials rule
would obviously no longer be fulfilled. The difference between the log-rank and Wald test is still surprising,
but a similar example has been reported in Collett (2003), example 3.3. I have decided to use the log-rank
p-values as reported, whereas the standard errors of log-hazard-ratios are used only to weight the harmonic
mean χ2- and Stouffer’s test. Likewise, the fixed and random-effects meta-analytic estimates are based on
effect estimates calculated from the p-values and the log-hazard-ratio standard errors reported in Table 1,
but the hazard ratios themselves are not used. Finally note that mortality was not the primary end point of
the various studies, but Fisher (1999a) argued that ‘it is the most important endpoint’ and ‘almost always
of primary importance to patients and their loved ones’.
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